Welcome to our dedicated page for AEGM news (Ticker: AEGM), a resource for investors and traders seeking the latest updates and insights on AEGM stock.
The AEGM news page on Stock Titan aggregates coverage related to Aethlon Medical, Inc., a clinical-stage medical device company focused on its Hemopurifier investigational device. Aethlon Medical reports that the Hemopurifier is designed to remove enveloped viruses, fragments of viruses, and tumor-derived extracellular vesicles from circulation, with potential applications in oncology and infectious disease.
News items for this company can include announcements about patents and intellectual property surrounding the Hemopurifier, such as protections for its use in Long COVID and COVID-19-associated coagulopathy. Updates may also highlight developments in the device’s research and development pathway, as well as commentary from company leadership about areas of significant unmet medical need.
Because the Hemopurifier holds U.S. Food and Drug Administration Breakthrough Device Designation for certain advanced cancer and life-threatening viral indications, regulatory and clinical context often features in company communications. Articles may discuss how the device is intended to work, including its use in an extracorporeal blood-pump circuit and its use of a plant lectin resin to target mannose-rich surfaces on extracellular vesicles and viral proteins.
Investors and observers who follow AEGM-related news can use this page to review how Aethlon Medical describes the evolution of its Hemopurifier platform, its patent portfolio, and its focus on oncology, infectious disease, Long COVID, and COVID-19-associated coagulopathy. Bookmark this page to quickly access new company press releases and related market coverage as they appear in the Stock Titan feed.
Aethlon Medical (Nasdaq: AEMD) has secured two significant patents for its Hemopurifier® device: U.S. Patent No. 12,409,260 for Long COVID treatment and European Patent 4136453 for COVID-19-associated coagulopathy (CAC) treatment. The U.S. patent, which expires in 2042, covers treating patients with reduced viral load but persistent Long COVID symptoms and the removal of circulating COVID-19 spike protein. The European patent, expiring in 2041, protects the Hemopurifier's use in treating CAC patients without circulating viral particles.
The U.S. patent received an additional 385-day term adjustment. CEO James Frakes emphasized that while the Hemopurifier® remains in R&D for Long COVID applications, these patents strengthen their intellectual property portfolio in areas with significant unmet medical needs.